drugset

drugset / Trial / NCT01229423

Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects

NCT01229423 ↗

Phase 4 Completed 62 enrolled Allergan

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of LATISSE® (bimatoprost 0.03%) in the augmentation of eyelashes in Korean women.

Timeline

Start: 2009-11
Primary completion: 2010-06
Completion: 2010-10

Publications

Background Kwon O, Kim JY, Paik SH, Jeon HC, Jung YJ, Lee Y, Baek JH, Chun JH, Lee WS, Lee JY, Rogers JD, Halstead M, Eun HC. Long-term utility and durability of the therapeutic effects of bimatoprost 0.03% for eyelash augmentation in healthy Asian subjects. Dermatology. 2014;229(3):222-9. doi: 10.1159/000363379. Epub 2014 Sep 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bimatoprost	Other / unclassified	0.03 %	Topical

Indications